For men who have had prostate gland removal surgery, results from a new study show that a combination of radiation treatment and androgen deprivation therapy is more effective for treating PSA recurrence than radiation alone.
The recommended guidelines for whether men should have the prostate cancer screening test have changed in recent years. A man considering the test should talk with his doctor and understand all the pros and cons involved.
In a British study, a specialized type of MRI test did significantly better at identifying high-grade prostate tumors than a transrectal ultrasound biopsy. It’s hoped that one day this test might help men avoid prostate biopsies and their potential complications.
After prostate cancer surgery, the patient’s prostate-specific antigen (PSA) is monitored by his doctor via a simple blood test. New research indicates that if the PSA increases following surgery, immediate radiation therapy can reduce the risk of cancer recurrence.
The Movember movement began in 2003 to help raise awareness of prostate and testicular cancers as well as other health concerns including mental health issues. One of the primary goals of this initiative is to encourage men to take the time to pay attention to their health. This includes doing self-exams and getting the necessary screenings so that cancers can be detected and treated earlier.
Two new studies add to the evidence that for many men with prostate cancer, if it is detected early and has not metastasized beyond the prostate gland, monitoring the cancer will lead to the same chance of survival after 10 as choosing surgery or radiation. Men treated with surgery or radiation often experience significant side effects. The rates of depression and anxiety were the same in men who opted for monitoring and those who opted for treatment.
For men with prostate cancer that has metastasized, treatment usually focuses on the tumors that develop elsewhere in the body. But treating the primary tumor in the prostate with radiation or surgery could result in longer overall survival.
Researchers believe that a non-invasive screening test that can identify genetic markers for high-grade prostate cancer in urine may eventually reduce the number of prostate biopsies needed. However, experts also caution that while the number of non-invasive tests for prostate cancer diagnosis is growing, these are still early days in their development.
Many men with prostate cancer benefit from active surveillance, in which treatment doesn’t begin unless the cancer spreads. There has been some debate about whether this strategy is safe for men with intermediate-risk prostate cancer. A new study suggests that this type of cancer is more likely to spread than previously thought — but active surveillance can still be a good option for many intermediate-risk men.
Long-term hormonal therapy, which blocks the effect of testosterone on prostate tumors, was once reserved for prostate cancer that has spread. But recent research has found that it had enormous benefits for men with earlier stages of prostate cancer, slashing their risks of metastasis and death from prostate cancer. However, some questions remain — for example, exactly how long to use “long-term hormonal therapy” is still up for debate.